pSivida Corp (PSDV) Announces France’s Transparency Commission Issues Positive Opinion for Reimbursement of ILUVIEN
7/24/2013 10:04:37 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that the Transparency Commission (Commission de la Transparence or CT) of the French National Health Authority (Haute Autorite de Sante) has issued a favorable opinion for the reimbursement and hospital listing by the French National Health Insurance of ILUVIEN® for the treatment of chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies and despite optimized management of diabetes. ILUVIEN is licensed to and sold by Alimera Sciences.
Help employers find you! Check out all the jobs and post your resume.
comments powered by